The deal is worth more than $225 million, sources told The New York Times.
Founded in 2017, Modern Fertility began by offering a $159 finger prick test that estimates how many eggs might be left in a person’s ovaries. The company now offers fertility tests, ovulation trackers, pregnancy tests and prenatal vitamins.
Modern Ferititly’s services will be integrated into Ro’s primary care platform, and Modern Fertility co-founders Afton Vechery and Carly Leahy will lead Ro’s women’s health offering.
“What excited us most about Modern Fertility is their relentless focus on the customer, their unique, proactive approach to fertility and women’s health, and the fact that Afton and Carly live and breathe Modern Fertility with every ounce of their being,” Ro CEO Zachariah Reitano said in a news release.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.